Immunohistochemical detection of receptor tyrosine kinases c-kit, EGF-R, and PDGF-R in colorectal adenocarcinomas

被引:9
作者
Friederichs, Jan [1 ,5 ]
von Weyhern, Claus W. H. [4 ]
Rosenberg, Robert [5 ]
Doll, Dietrich [5 ]
Busch, Raymonde [3 ]
Lordick, Florian [2 ]
Siewert, Joerg Ruediger [5 ]
Sarbia, Mario [4 ]
机构
[1] Tech Univ Munich, Klinikum Rechts Isar, Chirurg Klin & Poliklin, D-81675 Munich, Germany
[2] Tech Univ Munich, Klinikum Rechts Isar, Med Dept Hematol & Med Oncol 3, D-81675 Munich, Germany
[3] Tech Univ Munich, Klinikum Rechts Isar, Inst Med Stat & Epidemiol, D-81675 Munich, Germany
[4] Tech Univ Munich, Klinikum Rechts Isar, Inst Pathol, D-81675 Munich, Germany
[5] Tech Univ Munich, Klinikum Rechts Isar, Dept Surg, D-81675 Munich, Germany
关键词
Colorectal carcinoma; Tyrosine kinases; c-kit; GROWTH-FACTOR RECEPTOR; GASTROINTESTINAL STROMAL TUMORS; PROGNOSTIC-SIGNIFICANCE; MONOCLONAL-ANTIBODIES; PHASE-II; CANCER; EXPRESSION; CARCINOMA; CETUXIMAB; THERAPY;
D O I
10.1007/s00423-009-0478-8
中图分类号
R61 [外科手术学];
学科分类号
摘要
The selective inhibition of tyrosine kinases is a promising strategy in the treatment of several human malignancies. This study aimed to clarify expression patterns of therapeutically addressable receptor tyrosine kinases in colorectal cancer. In this study, we used tissue arrays to analyze 263 specimen of colorectal carcinoma for the expression of the tyrosine kinases c-kit (CD117), epidermal growth factor receptor (EGF-R), and platelet-derived growth factor receptor (PDGF-R). Staining patterns were then correlated with tumor stage and survival. Five tumors (1.9%) showed a strong expression of c-kit (CD117), while in 40 samples (15.2%), a weak/intermediate expression was observed. Positive staining did not correlate with histopathological parameters although a trend toward a better survival of c-kit-positive patients was observed. No positivity for PDGF-R was observed in 263 samples of colorectal carcinomas. Positive EGF-R expression was identified in 39 cases (15.2%), whereas 218 samples (84.8%) stained negative. Our study confirms that expression of the tyrosine kinases c-kit and PDGF-R are rare in colorectal carcinomas and do not correlate with tumor stage.
引用
收藏
页码:373 / 379
页数:7
相关论文
共 38 条
  • [1] Immunohistochemical detection of EGFR in paraffin-embedded tumor tissues:: Variation in staining intensity due to choice of fixative and storage time of tissue sections
    Atkins, D
    Reiffen, KA
    Tegtmeier, CL
    Winther, H
    Bonato, MS
    Störkel, S
    [J]. JOURNAL OF HISTOCHEMISTRY & CYTOCHEMISTRY, 2004, 52 (07) : 893 - 901
  • [2] Attoub S, 2002, CANCER RES, V62, P4879
  • [3] Bellone G, 2001, CANCER RES, V61, P2200
  • [4] Comparison of two antibodies for immunohistochemical evaluation of epidermal growth factor receptor expression in colorectal carcinomas, adenomas, and normal mucosa
    Bhargava, R
    Chen, BY
    Klimstra, DS
    Saltz, LB
    Hedvat, C
    Tang, LH
    Gerald, W
    Teruya-Feldstein, J
    Paty, PB
    Qin, J
    Shia, J
    [J]. CANCER, 2006, 106 (08) : 1857 - 1862
  • [5] Pharmacological background of EGFR targeting
    Castillo, L
    Etienne-Grimaldi, MC
    Fischel, JL
    Formento, P
    Magné, N
    Milano, G
    [J]. ANNALS OF ONCOLOGY, 2004, 15 (07) : 1007 - 1012
  • [6] Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer
    Cunningham, D
    Humblet, Y
    Siena, S
    Khayat, D
    Bleiberg, H
    Santoro, A
    Bets, D
    Mueser, M
    Harstrick, A
    Verslype, C
    Chau, I
    Van Cutsem, E
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2004, 351 (04) : 337 - 345
  • [7] Targeting c-kit mutations in solid tumors:: Scientific rationale and novel therapeutic options
    Demetri, GD
    [J]. SEMINARS IN ONCOLOGY, 2001, 28 (05) : 19 - 26
  • [8] Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors
    Demetri, GD
    von Mehren, M
    Blanke, CD
    Van den Abbeele, AD
    Eisenberg, B
    Roberts, PJ
    Heinrich, MC
    Tuveson, DA
    Singer, S
    Janicek, M
    Fletcher, JA
    Silverman, SG
    Silberman, SL
    Capdeville, R
    Kiese, B
    Peng, B
    Dimitrijevic, S
    Druker, BJ
    Corless, C
    Fletcher, CDM
    Joensuu, H
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2002, 347 (07) : 472 - 480
  • [9] Protocol modifications influence the result of EGF receptor immunodetection by EGFR pharmDX™ in paraffin-embedded cancer tissues
    Derecskei, Katalin
    Moldvay, Judit
    Bogos, Krisztina
    Timar, Jozsef
    [J]. PATHOLOGY & ONCOLOGY RESEARCH, 2006, 12 (04) : 243 - 246
  • [10] New treatment options for colorectal cancer
    Erlichman, C
    Sargent, DJ
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2004, 351 (04) : 391 - 392